Bextra is a drug owned by Gd Searle Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 13, 2015. Details of Bextra's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5633272 | Substituted isoxazoles for the treatment of inflammation |
Feb, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Bextra is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bextra's family patents as well as insights into ongoing legal events on those patents.
Bextra's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bextra's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 13, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bextra Generics:
There are no approved generic versions for Bextra as of now.
About Bextra
Bextra is a drug owned by Gd Searle Llc. It is used for managing symptoms of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea. Bextra uses Valdecoxib as an active ingredient. Bextra was launched by Gd Searle in 2001.
Approval Date:
Bextra was approved by FDA for market use on 16 November, 2001.
Active Ingredient:
Bextra uses Valdecoxib as the active ingredient. Check out other Drugs and Companies using Valdecoxib ingredient
Treatment:
Bextra is used for managing symptoms of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea.
Dosage:
Bextra is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG | TABLET | Discontinued | ORAL |
| 20MG | TABLET | Discontinued | ORAL |